About Kinnate Biopharma
Kinnate Biopharma is a Healthcare company based in San Diego (United States) founded in 2018 by Eric Murphy and Steve Kaldor, and was acquired by XOMA Corporation in February 2024. Small molecule therapeutics for cancer treatment are developed. Kinnate Biopharma has raised $172.5 million across 2 funding rounds from investors including Fidelity Investments, Citadel and Orbimed. The company has 30 employees. Its chief executive, as recorded, is Steve Kaldor. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is KINNATE BIOPHARMA INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Kinnate Biopharma was founded in 2018 and is headquartered in San Diego, United States. Small molecule therapeutics are developed for cancer treatment within the biopharmaceutical sector. Operations center on three programs: precision oncology targeting DNA damage repair mechanisms, inhibitors addressing gene rearrangements with known resistance mutations, and inhibitors for a pathway validated clinically across various cancers.
- Headquarters San Diego, United States
- Employees 30
- Founders Eric Murphy, Steve Kaldor
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website kinnate.com
- Social LinkedIn
- Acquired by XOMA Corporation (Feb 2024)
- Legal Name Kinnate Biopharma Inc.
- Net Profit-$112.65 M (USD)3as on Dec 31, 2023
- EBITDA-$121.18 M (USD)-2as on Dec 31, 2023
- Total Equity Funding$172.5M (USD)
in 2 rounds
- Latest Funding Round$98M (USD), Series C
Jul 2020
- InvestorsFidelity Investments
& 14 more
- Employee Count30
- Acquired byXOMA Corporation
(Feb 2024)
Funding Insights of Kinnate Biopharma
Kinnate Biopharma has successfully raised a total of $172.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $98 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $172.5M
- Total Rounds 2
- Last Round Series C — $98M
- First Round $74.5M
(Dec 2019)
- Investors Count 14
All 2 funding rounds of Kinnate Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $98M | Series C | – | RA Capital Management | |
| Dec 2019 | $74.5M | Series B | – | Orbimed, Nextech Invest |
15 investors in total: 15 institutional.
Investors in Kinnate Biopharma
Kinnate Biopharma has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Citadel and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Tavistock Group is engaged in global diversified investments. | tavistock.com | |||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
| eshelmanventures.com | ||||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Kinnate Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kinnate Biopharma
25 people are tracked at Kinnate Biopharma (13 in leadership, 7 in board & advisors, 5 in team); the tracked headcount is 30.
| Name | Role | Group |
|---|---|---|
Eric Murphy | Co-Founder & CSO | Leadership |
Steve Kaldor | Co-Founder & CEO | Leadership |
James R. Neal | CEO | Leadership |
Al Dadson | Vice President, Manufacturing Operations & Facilities Engineering | Leadership |
Jessica Holden | Group CFO | Leadership |
Lisa Christensen | Executive Assistant to the CEO | Leadership |
Fred Kurland | Vice President, Finance and Chief Financial Officer | Leadership |
Christine Theriault, CPA | Vice President, Corporate Controller | Leadership |
Christopher Baldwin | Vice President, Legal | Leadership |
Nicholas A. Cole | Vice President, Finance & Acquisitions | Leadership |
Brad Sitko | Chief Investment Officer | Leadership |
Thomas Burns | Senior Vice President, Finance and CFO | Leadership |
Peter Rehnquist | Director Corporate Development | Leadership |
Barbara Kosacz | Director | Board & advisors |
Joseph M. Limber | Director | Board & advisors |
Matthew Perry | Director | Board & advisors |
Jack L. Wyszomierski | Director | Board & advisors |
Natasha Hernday | Director | Board & advisors |
Heather L. Franklin | Director | Board & advisors |
Owen Hughes | Executive Chairman | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for Kinnate Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kinnate Biopharma
4 dated milestones of Kinnate Biopharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Kinnate Biopharma is founded.
- Funding First funding round of $74.5M.
- Funding Latest funding round, Series C, of $98.0M.
- Exit Acquired by XOMA Corporation.
Competitors of Kinnate Biopharma
Kinnate Biopharma has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Kinnate Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Kinnate Biopharma (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kinnate Biopharma
Complete news archive for Kinnate Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kinnate Biopharma
Kinnate Biopharma was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Kinnate Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Steve Kaldor is the CEO of Kinnate Biopharma, as recorded in our data. They have also founded this company.
Kinnate Biopharma is a funded company, having raised a total of $172.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $74.5M, raised on Dec 2019.
Kinnate Biopharma has 30 employees.
Kinnate Biopharma was founded in 2018 and is headquartered in San Diego, United States. Small molecule therapeutics are developed for cancer treatment within the biopharmaceutical sector. Operations center on three programs: precision oncology targeting DNA damage repair mechanisms, inhibitors addressing gene rearrangements with known resistance mutations, and inhibitors for a pathway validated clinically across various cancers.
Kinnate Biopharma has 15 investors. Key investors include Fidelity Investments, Citadel, Orbimed, Janus Henderson Investors, and RA Capital.
Kinnate Biopharma operates through Kinnate Biopharma Inc..
Yes. Kinnate Biopharma was acquired by XOMA Corporation in February 2024.